0001104659-24-043104.txt : 20240403
0001104659-24-043104.hdr.sgml : 20240403
20240403161041
ACCESSION NUMBER: 0001104659-24-043104
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240402
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sandrock Alfred
CENTRAL INDEX KEY: 0001577061
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37625
FILM NUMBER: 24818790
MAIL ADDRESS:
STREET 1: 14 CAMBRIDGE CENTER
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Voyager Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640266
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 857-259-5340
MAIL ADDRESS:
STREET 1: 75 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
tm2410775-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-04-02
0
0001640266
Voyager Therapeutics, Inc.
VYGR
0001577061
Sandrock Alfred
C/O VOYAGER THERAPEUTICS, INC.
75 HAYDEN AVENUE
LEXINGTON
MA
02421
1
1
0
0
President and CEO
0
Common Stock
2024-04-02
4
S
0
12115
9.86
D
322839
D
Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2024. The sales do not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.71 to $10.02, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
/s/ Scott MacDonald, as Attorney-in-Fact for Alfred Sandrock
2024-04-03